| Regulated Markets Business | Development, manufacturing, and marketing of specialty pharmaceutical products primarily for US, Canada, and UK markets. | USFDA approved facilities, DEA compliance, long-term marketing agreements, and proprietary product pipeline. | Pharmaceutical companies and healthcare providers in regulated markets (B2B). | Specialty niche products, controlled substances, and complex formulations. | 245 | 58 | Revenue from licensing, product commercialization, profit sharing, and long-term marketing agreements. | Contractual licensing fees, transfer pricing, and profit-sharing arrangements. | Strong product pipeline with 22 ANDAs under development, regulatory approvals, US market penetration, and acquisitions. | 46 Approved ANDAs with 137 strengths, 18 commercialized ANDAs |
| Emerging Markets Business | Manufacturing and marketing of generic formulations and branded generics in emerging markets across Asia, Africa, Latin America, and Middle East. | WHO-GMP compliant manufacturing, diverse product portfolio, and distribution partnerships. | Pharmacies, hospitals, and distributors in emerging markets (B2B and B2C). | Branded generics with established market presence. | 8 | 2 | Sales revenue through distributor networks and direct marketing. | Direct sales with pricing competitive in emerging markets. | Expanding product registrations, geographic reach, and enhanced marketing efforts. | 450+ branded generics products registered in 40+ countries. |
| Critical Care Injectables Business | Manufacture and distribution of injectables to hospitals and healthcare providers across India. | Strong field presence with 104 employees and distributor network. | Hospitals, healthcare providers, distributors in India (B2B). | Injectables with niche critical care indications. | 121 | 29 | Revenue from product sales through distributor channels. | Sales through distributors with competitive pricing. | Growing domestic hospital demand and new product launches. | 60 critical care injectable products supplied across India. |
| API Business | Manufacturing of active pharmaceutical ingredients for domestic and SAARC countries markets. | In-house API manufacturing reduces supply chain dependency and cost. | Pharmaceutical formulation companies in domestic and nearby markets (B2B). | Selective APIs with high demand and regulatory approvals. | 14 | 3 | Sales of APIs to pharmaceutical manufacturers. | Direct sales to manufacturers. | Investment in greenfield API plant, backward integration strategies. | |
